XERS - Xeris Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
1,692
2,465
1,556
1,075
Cost of Revenue
33
42
4
8
Gross Profit
1,659
2,423
1,552
1,067
Operating Expenses
Research Development
60,408
40,654
20,166
10,238
Selling General and Administrative
51,144
21,113
8,015
4,060
Total Operating Expenses
111,552
61,767
28,181
14,298
Operating Income or Loss
-109,893
-59,344
-26,629
-13,231
Interest Expense
6,687
2,545
2
2
Total Other Income/Expenses Net
673
196
-47
19
Income Before Tax
-112,917
-60,080
-26,554
-13,209
Income Tax Expense
-
-
-
-
Income from Continuing Operations
-112,917
-60,080
-26,554
-13,209
Net Income
-112,917
-60,080
-26,554
-13,209
Net Income available to common shareholders
-112,917
-60,080
-26,554
-13,209
Reported EPS
Basic
-
-4.99
-2.34
-6.09
Diluted
-
-4.99
-2.34
-6.09
Weighted average shares outstanding
Basic
-
12,046
11,359
2,170
Diluted
-
12,046
11,359
2,170
EBITDA
-
-57,215
-26,375
-13,091